SEATTLE — Omeros Corporation on Thursday reported a loss of $14.5 million in its second quarter.
The Seattle-based company said it had a loss of 29 cents per share. Losses, adjusted for stock option expense, were 16 cents per share.
The drug developer posted revenue of $26.8 million in the period.
Omeros shares have climbed 46 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $16.31, a fall of 25 percent in the last 12 months.
